- Home
- ACHC vs CERT Comparison
ACHC vs CERT Comparison
Compare ACHC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | CERT |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHC | CERT |
|---|---|---|
| Price | $11.73 | $9.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $20.50 | $12.78 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | 0.07 |
| Revenue | ★ $3,265,548,000.00 | $415,551,000.00 |
| Revenue This Year | $6.50 | $10.80 |
| Revenue Next Year | $4.38 | $6.47 |
| P/E Ratio | ★ $10.64 | $135.27 |
| Revenue Growth | 4.58 | ★ 11.47 |
| 52 Week Low | $12.49 | $8.03 |
| 52 Week High | $47.08 | $15.69 |
Technical Indicators
Market Signals| Indicator | ACHC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 24.95 | 53.15 |
| Support Level | $12.85 | $9.10 |
| Resistance Level | $13.85 | $9.45 |
| Average True Range (ATR) | 0.69 | 0.29 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 0.15 | 58.02 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.